Rankings
▼
Calendar
CTNM
Contineum Therapeutics, Inc. Class A Common Stock
$504M
Q4 2022 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$0
Gross Profit
-$81,000
Operating Income
-$5M
Net Income
-$8M
EPS (Diluted)
$-0.30
Cash Flow
Operating Cash Flow
-$4M
Free Cash Flow
-$4M
Stock-Based Comp.
$491,000
Balance Sheet
Total Assets
$51M
Total Liabilities
$11M
Stockholders' Equity
$39M
Cash & Equivalents
$6M
← FY 2022
All Quarters
Q1 2023 →
CTNM Q4 2022 Earnings — Contineum Therapeutics, Inc. Class A Common Stock Revenue & Financial Results | Market Cap Arena
